#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Meningococcal immunisation Colitis ulcerative Arterial disorder Selective polysaccharide antibody deficiency Becker's muscular dystrophy Breast angiosarcoma Renal cancer metastatic Leukoencephalopathy Mixed-type liposarcoma Hodgkin's disease refractory Aicardi-Goutieres syndrome ABO haemolytic disease of newborn Retinitis pigmentosa Stargardt's disease Infection in an immunocompromised host More trials…

    Learn about Rare Diseases

    Angiosarcoma recurrent Combined immunodeficiency – Life with Disease Hereditary angioedema with C1 esterase inhibitor deficiency – Treatment Bronchiolitis obliterans syndrome – Diagnostics Primary biliary cholangitis – Basic Information Pleural mesothelioma malignant – Basic Information Idiopathic inflammatory myopathy Ocular melanoma – Basic Information Erdheim-Chester disease – Diagnostics Adrenogenital syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ag13909 Gliquidone Leriglitazone WEF-001 Tobevibart Regtivex ULTEVURSEN Mirtazapine Albiglutide Tezacaftor NVG-2089 Pasireotide Tamibarotene Skin Autograft Capivasertib Imlifidase Ovolecithin Metformin Embonate OMECAMTIV MECARBIL Fluticasone Propionate More therapies…

    Learn about Your Condition

    Sepsis Leukaemia Milk allergy Metastatic neoplasm Vulval cancer recurrent Lymphangiosarcoma Colorectal cancer Pharyngeal cancer stage III Rheumatic disorder Hypochromic anaemia Lung cancer metastatic Melanoma recurrent Sinusitis bacterial Breast neoplasm Pericarditis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. University Of Debrecen

University Of Debrecen

Mlkyto Zwymatyw Kjsmn 2bd Dgzlrqljq 4zclk Hqzliqx

Want to learn more about this study or check if you can participate? Contact us.

  • Efficacy and Safety of MET097 Once Weekly in People with Overweight or Obesity and Type 2 Diabetes

    Not recruiting

    3 1
    Bulgaria Czechia Germany Hungary Poland Romania +2

  • Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study

    Not recruiting

    3 1
    Investigated Drugs:
    • Itepekimab
    Austria Belgium Czechia Denmark Finland France +9

  • A study to test if tibulizumab works and is safe for adults with systemic sclerosis

    Not recruiting

    2 1
    Investigated Diseases:
    • Systemic scleroderma
    Hungary Poland Romania Spain

  • A Study of Cagrilintide and Semaglutide for Weight Loss in People with Type 2 Diabetes and Overweight or Obesity

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Obesity
    • Overweight
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Cagrilintide
    • Semaglutide
    Austria Germany Hungary Ireland Poland

  • Study on Dupilumab for Itch Relief in Adults with Lichen Simplex Chronicus (Neurodermatitis)

    Not recruiting

    3 1
    Investigated Diseases:
    • Neurodermatitis
    Investigated Drugs:
    • Dupilumab
    Belgium Czechia Germany Greece Hungary Italy +2

  • Study on the Effects of Pelacarsen on Heart Disease in Patients with Cardiovascular Conditions

    Not recruiting

    3 1
    Investigated Drugs:
    • Pelacarsen
    Austria Belgium Bulgaria Czechia Denmark France +14

  • Study on the Effects and Safety of Guselkumab for Patients with Active Psoriatic Arthritis

    Not recruiting

    3 1
    Investigated Drugs:
    • Guselkumab
    Bulgaria Croatia Czechia Estonia Germany Greece +8

  • Study on INZ-701 for Improving Survival in Infants with ENPP1 Deficiency

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency
    Investigated Drugs:
    • Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
    France Hungary Italy Spain Sweden

  • Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma
    Investigated Drugs:
    • Tafasitamab
    • Betamethasone Sodium Phosphate
    • Cyclophosphamide
    Austria Czechia France Germany Hungary Ireland +5

  • Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dry eye
    • Sjogren’s syndrome
    Investigated Drugs:
    • Entecavir
    • Ianalumab
    • Emtricitabine
    Austria Belgium Bulgaria Czechia France Germany +10
Previous Page
1 … 49 50 51 52
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!